ID: h-2416d8f8d2
Hypothesis
Synaptic protection via microglial/complement normalization
Cancer-induced cystatin C prevents complement-mediated synaptic loss through TREM2-mediated microglial phenotype regulation, reducing C1q/C3 deposition and excessive pruning.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Cancer-induced cystatin C prevents complement-mediated synaptic loss through TREM2-mediated microglial phenotype regulation, reducing C1q/C3 deposition and excessive pruning. This is clinically important but probably secondary to plaque remodeling plus microglial state change rather than a distinct mechanism. Synaptic biomarkers are noisy and slower-moving than amyloid PD markers, making mechanism proof difficult in humans.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
B["TREM2 Receptor<br/>Ligand Binding"]
C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
D["SYK Kinase<br/>Activation"]
E["PLCG2<br/>IP3 + DAG Generation"]
F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
G["Microglial Phagocytosis<br/>Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Contradicts
TREM2 loss-of-function shows baseline requirement, not that activation improves pruning
Contradicts
Cachexia confounding in cancer-bearing mice may affect synaptic plasticity independently
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2/complement cascade from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.2%
Volatility
Low
0.0042
Events (7d)
2
Price History
▼5.6%💾 Resource Usage
LLM Tokens
11,154
$0.0335
Total Cost
$0.0335
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we pharmacologically activate TREM2 signaling (using TREM2 agonistic antibody or TREM2 SLP variant) in 5xFAD mice during early amyloid pathology THEN we will observe a significant reduction in post | ≥30% reduction in synaptic complement deposition (C1q/C3 western blot of synaptoneurosomes) and ≥25% preservation of PSD-95+ dendritic spine density in hippocam | — no observation — | pending | 0.65 |
| IF we stratify human ADNI-3 and DIAN cohorts by tertiles of plasma cystatin C levels and TREM2 loss-of-function variant carrier status THEN we will observe that high cystatin C + functional TREM2 geno | ≥40% slower annual decline in CSF synaptic marker concentrations and ≥2-point better ADAS-Cog13 score in high cystatin C + TREM2 functional group vs low cystati | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we pharmacologically activate TREM2 signaling (using TREM2 agonistic antibody or TREM2 SLP variant) in 5xFAD mice during early amyloid pathology THEN we will observe a significant reduction in postsynaptic density protein-95 (PSD-95) loss and C1q/C3 deposition at excitatory synapses compared to v
Predicted outcome: ≥30% reduction in synaptic complement deposition (C1q/C3 western blot of synaptoneurosomes) and ≥25% preservation of PSD-95+ dendritic spine density i
Falsification: No significant difference (p>0.05) in synaptic complement deposition or PSD-95 levels between TREM2-activated and control groups, OR increased complement activation indicating pathway engagement failu
pendingconf 55%
IF we stratify human ADNI-3 and DIAN cohorts by tertiles of plasma cystatin C levels and TREM2 loss-of-function variant carrier status THEN we will observe that high cystatin C + functional TREM2 genotype will be associated with slower decline in CSF synaptic biomarkers (SNAP-25, synaptotagmin-1) an
Predicted outcome: ≥40% slower annual decline in CSF synaptic marker concentrations and ≥2-point better ADAS-Cog13 score in high cystatin C + TREM2 functional group vs l
Falsification: No significant association between cystatin C levels or TREM2 status and synaptic biomarker trajectories (p>0.05), OR paradoxical accelerated decline in high cystatin C group indicating compensatory r
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.